Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs
Open Access
- 14 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 26 (5), 678-686
- https://doi.org/10.1093/ibd/izz329
Abstract
Intestinal fibrosis is a hallmark of Crohn’s disease. Here, we investigated the impact of several putative antifibrotic compounds on the expression of fibrosis markers using murine precision-cut intestinal slices. Murine precision-cut intestinal slices were cultured for 48 hours in the presence of profibrotic and/or antifibrotic compounds. The fibrotic process was studied on gene and protein level using procollagen 1a1 (Col1α1), heat shock protein 47 (Hsp47), fibronectin (Fn2), and plasminogen activator inhibitor-1 (Pai-1). The effects of potential antifibrotic drugs mainly inhibiting the transforming growth factor β (TGF-β) pathway (eg, valproic acid, tetrandrine, pirfenidone, SB203580, and LY2109761) and compounds mainly acting on the platelet-derived growth factor (PDGF) pathway (eg, imatinib, sorafenib, and sunitinib) were assessed in the model at nontoxic concentrations. Murine precision-cut intestinal slices remained viable for 48 hours, and an increased expression of fibrosis markers was observed during culture, including Hsp47, Fn2, and Pai-1. Furthermore, TGF-β1 stimulated fibrogenesis, whereas PDGF did not have an effect. Regarding the tested antifibrotics, pirfenidone, LY2109761, and sunitinib had the most pronounced impact on the expression of fibrosis markers, both in the absence and presence of profibrotic factors, as illustrated by reduced levels of Col1α1, Hsp47, Fn2, and Pai-1 after treatment. Moreover, sunitinib significantly reduced Hsp47 and Fn2 protein expression and the excretion of procollagen 1. Precision-cut intestinal slices can successfully be used as a potential preclinical screening tool for antifibrotic drugs. We demonstrated that sunitinib reduced the expression of several fibrosis markers, warranting further evaluation of this compound for the treatment of intestinal fibrosis.Keywords
Funding Information
- De Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie (114025003)
This publication has 48 references indexed in Scilit:
- Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosisBritish Journal of Pharmacology, 2017
- Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosisToxicology in Vitro, 2016
- Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBDJournal of Crohn's and Colitis, 2014
- Crohn's disease complicated by strictures: a systematic reviewGut, 2013
- Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human diseaseAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Platelet-derived growth factor receptor signaling activates pericyte–myofibroblast transition in obstructive and post-ischemic kidney fibrosisKidney International, 2011
- Intestinal fibrosis in Crohn's disease: medical treatment or surgery?Current Drug Targets, 2010
- Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cellsin vitroandin vivoHepatology, 2009
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic ratsHepatology, 2008
- Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat modelWorld Journal of Gastroenterology, 2007